Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Trial Identifier: EFC15150
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: October 2020
Primary Completion Date: January 2021
Study Completion Date: January 2021
Condition: Influenza Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
JAPAN Fukuoka-Shi, JAPAN
JAPAN Koganei-Shi, JAPAN
JAPAN Kumamoto-Shi, JAPAN
JAPAN Osaka-Shi, JAPAN
JAPAN Shinjuku-Ku, JAPAN
JAPAN Suita-Shi, JAPAN
JAPAN Toshima-Ku, JAPAN
JAPAN Yokohama-Shi, JAPAN